Drugs / [211At]NaAt
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07287748 | Jan 2026 → Jul 2028 expected | differentiated thyroid carcinoma | Alpha Fusion Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [211At]NaAt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07287748 ↗ |
| Known as | af-001 | “A Phase I Trial of the Alpha Particle-emitting Radiopharmaceutical, Af-001, in Patients With Differentiated Thyroid Cancer” NCT07287748 ↗ |
| Modality | Other / unclassified | “Alpha Particle-emitting Radiopharmaceutical” NCT07287748 ↗ |
| Route | Intravenous | “single intravenous dose of af-001” NCT07287748 ↗ |